Involvement of advanced glycation end product-induced asymmetric dimethylarginine generation in endothelial dysfunction

Diabetes and Vascular Disease Research

Volumn 10, Issue 5, 2013, Pages 436-441

  Ando, Ryotaro ^a   Ueda, Seiji ^a   Yamagishi, Sho Ichi ^a   Miyazaki, Hiroshi ^a   Kaida, Yusuke ^a   Kaifu, Kumiko ^a   Yokoro, Miyuki ^a   Nakayama, Yosuke ^a   Obara, Nana ^a   Fukami, Kei ^a   Takeuchi, Masayoshi ^b   Okuda, Seiya ^a  

^a KURUME UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^b KANAZAWA MEDICAL UNIVERSITY   (Japan)

Author keywords

Atherosclerosis; endothelial dysfunction; nitric oxide; oxidative stress

Indexed keywords

ADVANCED GLYCATION END PRODUCT; COMPLEMENTARY DNA; DIMETHYLARGININASE; MESSENGER RNA; N(G),N(G) DIMETHYLARGININE; REACTIVE OXYGEN METABOLITE;

ADULT; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; DIABETIC NEPHROPATHY; ENDOTHELIAL DYSFUNCTION; ENDOTHELIUM CELL; ENZYME ACTIVITY; ENZYME BLOOD LEVEL; FEMALE; HUMAN; HUMAN CELL; KIDNEY FAILURE; MALE; VASODILATATION;

ATHEROSCLEROSIS; ENDOTHELIAL DYSFUNCTION; NITRIC OXIDE; OXIDATIVE STRESS;

AGED; AMIDOHYDROLASES; ARGININE; ATHEROSCLEROSIS; CELLS, CULTURED; DIABETIC NEPHROPATHIES; ENDOTHELIAL CELLS; FEMALE; GLYCOSYLATION END PRODUCTS, ADVANCED; HUMANS; MALE; MIDDLE AGED; NITRIC OXIDE; REACTIVE OXYGEN SPECIES; VASCULAR DISEASES;

EID: 84882322069     PISSN: 14791641     EISSN: 17528984     Source Type: Journal    
DOI: 10.1177/1479164113486662     Document Type: Article

References (30)

1. Brownlee M, Cerami A, Vlassara H. Advanced glycosylation end products in tissue and the biochemical basis of diabetic complications. N Engl J Med. 1988 ; 318: 1315-1321
2. Bucala R, Cerami A. Chemistry, biology, and implications for diabetes and aging. Adv Pharmacol. 1992 ; 23: 1-34
3. Makita Z, Radoff S, Rayfield EJ, et al. Advanced glycation end products in diabetic nephropathy. N Engl J Med. 1991 ; 325: 836-842
4. Yamagishi S, Nakamura K, Matsui T, et al. Receptor for advanced glycation end products (RAGE): a novel therapeutic target for diabetic vascular complication. Curr Pharm Des. 2008 ; 14: 487-495
5. Donato R. RAGE: a single receptor for several ligands and different cellular responses: the case of certain S100 proteins. Curr Mol Med. 2007 ; 7: 711-724
6. Yamagishi S, Imaizumi T. Diabetic vascular complications: pathophysiology, biochemical basis and potential therapeutic strategy. Curr Pharm Des. 2005 ; 11: 2279-2299
7. Baylis C. Nitric oxide deficiency in chronic kidney disease. Am J Physiol Renal Physiol. 2008 ; 294: F1 - F9
8. Böger RH, Bode-Böger SM, Frölich JC. The L-arginine-nitric oxide pathway: role in atherosclerosis and therapeutic implications. Atherosclerosis. 1996 ; 127: 1-11
9. Ueda S, Yamagishi S, Okuda S. New pathways to renal damage: role of ADMA in retarding renal disease progression. J Nephrol. 2010 ; 23: 377-386
10. Tarnow L, Hovind P, Teerlink T, et al. Elevated plasma asymmetric dimethylarginine as a marker of cardiovascular morbidity in early diabetic nephropathy in type 1 diabetes. Diabetes Care. 2004 ; 27: 765-769
11. Ueda S, Matsuoka H, Miyazaki H, et al. Tetrahydrobiopterin restores endothelial function in long-term smokers. J Am Coll Cardiol. 2000 ; 35: 71-75
12. Ueda S, Kato S, Matsuoka H, et al. Regulation of cytokine-induced nitric oxide synthesis by asymmetric dimethylarginine: role of dimethylarginine dimethylaminohydrolase. Circ Res. 2003 ; 92: 226-233
13. Fukami K, Ueda S, Yamagishi S, et al. AGEs activate mesangial TGF-beta-Smad signaling via an angiotensin II type I receptor interaction. Kidney Int. 2004 ; 66: 2137-2147
14. Kato S, Sasaguri Y, Azakami S, et al. Ambient pressure stimulates immortalized human aortic endothelial cells to increase DNA synthesis and matrix metalloproteinase 1 (tissue collagenase) production. Virchows Arch. 1994 ; 425: 385-390
15. Yamagishi S, Yamamoto Y, Harada S, et al. Advanced glycosylation end products stimulate the growth but inhibit the prostacyclin-producing ability of endothelial cells through interactions with their receptors. FEBS Lett. 1996 ; 384: 103-106
16. Inagaki Y, Yamagishi S, Okamoto T, et al. Pigment epithelium-derived factor prevents advanced glycation end products-induced monocyte chemoattractant protein-1 production in microvascular endothelial cells by suppressing intracellular reactive oxygen species generation. Diabetologia. 2003 ; 46: 284-287
17. Nakamura T, Sato E, Fujiwara N, et al. Positive association of serum levels of advanced glycation end products and high mobility group box-1 with asymmetric dimethylarginine in nondiabetic chronic kidney disease patients. Metabolism. 2009 ; 58: 1624-1628
18. Tan KC, Chow WS, Ai VH, et al. Advanced glycation end products and endothelial dysfunction in type 2 diabetes. Diabetes Care. 2002 ; 25: 1055-1059
19. Bucala R, Tracey KJ, Cerami A. Advanced glycosylation products quench nitric oxide and mediate defective endothelium-dependent vasodilatation in experimental diabetes. J Clin Invest. 1991 ; 87: 432-438
20. Wautier MP, Chappey O, Corda S, et al. Activation of NADPH oxidase by AGE links oxidant stress to altered gene expression via RAGE. Am J Physiol Endocrinol Metab. 2001 ; 280: E685 - E694
21. Leiper J, Maria J, Chubb A, et al. Identification of two human dimethylarginine dimethylaminohydrolases with distinct tissue distributions and homology with microbial arginine deiminases. Biochem J. 1999 ; 343: 209-214
22. Lin KY, Ito A, Asagami T, et al. Impaired nitric oxide synthase pathway in diabetes mellitus: role of asymmetric dimethylarginine and dimethylarginine dimethylaminohydrolase. Circulation. 2002 ; 106: 987-992
23. Lu CW, Guo Z, Feng M, et al. Ex vivo gene transferring of human dimethylarginine dimethylaminohydrolase-2 improved endothelial dysfunction in diabetic rat aortas and high glucose-treated endothelial cells. Atherosclerosis. 2010 ; 209: 66-73
24. Zoccali C, Benedetto FA, Maas R, et al. CREED Investigators. Asymmetric dimethylarginine, c-reactive protein, and carotid intima-media thickness in end-stage renal disease. J Am Soc Nephrol. 2002 ; 13: 490-496
25. Valkonen VP, Paiva H, Salonen JT, et al. Risk of acute coronary events and serum concentration of asymmetrical dimethylarginine. Lancet. 2001 ; 358: 2127-2128
26. Zoccali C, Bode-Böger SM, Mallamaci F, et al. Plasma concentration of asymmetrical dimethylarginine and mortality in patients with end-stage renal disease: a prospective study. Lancet. 2001 ; 358: 2113-2117
27. Wang D, Gill PS, Chabrashvili T, et al. Isoform-specific regulation by N(G),N(G)-dimethylarginine dimethylaminohydrolase of rat serum asymmetric dimethylarginine and vascular endothelium-derived relaxing factor/NO. Circ Res. 2007 ; 101: 627-635
28. Hu X, Xu X, Zhu G, et al. Vascular endothelial-specific dimethylarginine dimethylaminohydrolase-1-deficient mice reveal that vascular endothelium plays an important role in removing asymmetric dimethylarginine. Circulation. 2009 ; 120: 2222-2229
29. Wagner Z, Wittmann I, Mazák I, et al. N(epsilon)-(carboxymethyl) lysine levels in patients with type 2 diabetes: role of renal function. Am J Kidney Dis. 2001 ; 38: 785-791
30. Hirata K, Kubo K. Relationship between blood levels of N-carboxymethyl-lysine and pentosidine and the severity of microangiopathy in type 2 diabetes. Endocr J. 2004 ; 51: 537-544